Literature DB >> 29996072

Promise of Immune Therapies in Multiple Myeloma.

Kenneth C Anderson1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29996072      PMCID： PMC6045492          DOI： 10.1200/JOP.18.00311

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.714


× No keyword cloud information.
  21 in total

1.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Authors:  Yu-Tzu Tai; Patrick A Mayes; Chirag Acharya; Mike Y Zhong; Michele Cea; Antonia Cagnetta; Jenny Craigen; John Yates; Louise Gliddon; William Fieles; Bao Hoang; James Tunstead; Amanda L Christie; Andrew L Kung; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2014-02-25       Impact factor: 22.113

2.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Authors:  Sagar Lonial; Meletios Dimopoulos; Antonio Palumbo; Darrell White; Sebastian Grosicki; Ivan Spicka; Adam Walter-Croneck; Philippe Moreau; Maria-Victoria Mateos; Hila Magen; Andrew Belch; Donna Reece; Meral Beksac; Andrew Spencer; Heather Oakervee; Robert Z Orlowski; Masafumi Taniwaki; Christoph Röllig; Hermann Einsele; Ka Lung Wu; Anil Singhal; Jesus San-Miguel; Morio Matsumoto; Jessica Katz; Eric Bleickardt; Valerie Poulart; Kenneth C Anderson; Paul Richardson
Journal:  N Engl J Med       Date:  2015-06-02       Impact factor: 91.245

3.  Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

Authors:  Güllü Görgün; Mehmet K Samur; Kristen B Cowens; Steven Paula; Giada Bianchi; Julie E Anderson; Randie E White; Ahaana Singh; Hiroto Ohguchi; Rikio Suzuki; Shohei Kikuchi; Takeshi Harada; Teru Hideshima; Yu-Tzu Tai; Jacob P Laubach; Noopur Raje; Florence Magrangeas; Stephane Minvielle; Herve Avet-Loiseau; Nikhil C Munshi; David M Dorfman; Paul G Richardson; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

4.  Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

Authors:  Noopur Raje; Evangelos Terpos; Wolfgang Willenbacher; Kazuyuki Shimizu; Ramón García-Sanz; Brian Durie; Wojciech Legieć; Marta Krejčí; Kamel Laribi; Li Zhu; Paul Cheng; Douglas Warner; G David Roodman
Journal:  Lancet Oncol       Date:  2018-02-09       Impact factor: 41.316

5.  A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

Authors:  S Hipp; Y-T Tai; D Blanset; P Deegen; J Wahl; O Thomas; B Rattel; P J Adam; K C Anderson; M Friedrich
Journal:  Leukemia       Date:  2016-12-27       Impact factor: 11.528

6.  APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

Authors:  Yu-Tzu Tai; Chirag Acharya; Gang An; Michele Moschetta; Mike Y Zhong; Xiaoyan Feng; Michele Cea; Antonia Cagnetta; Kenneth Wen; Hans van Eenennaam; Andrea van Elsas; Lugui Qiu; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

7.  Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.

Authors:  Paul G Richardson; Michel Attal; Frank Campana; Solenn Le-Guennec; Ai-Min Hui; Marie-Laure Risse; Kathryn Corzo; Kenneth C Anderson
Journal:  Future Oncol       Date:  2017-12-22       Impact factor: 3.404

Review 8.  Present and Future of Immunotherapy in the Management of Multiple Myeloma.

Authors:  Muhamed Baljevic; Sarah A Holstein
Journal:  J Oncol Pract       Date:  2018-07       Impact factor: 3.840

Review 9.  Dendritic Cell Therapies for Hematologic Malignancies.

Authors:  Matthew Weinstock; Jacalyn Rosenblatt; David Avigan
Journal:  Mol Ther Methods Clin Dev       Date:  2017-03-18       Impact factor: 6.698

10.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Authors:  Jens G Lohr; Petar Stojanov; Scott L Carter; Peter Cruz-Gordillo; Michael S Lawrence; Daniel Auclair; Carrie Sougnez; Birgit Knoechel; Joshua Gould; Gordon Saksena; Kristian Cibulskis; Aaron McKenna; Michael A Chapman; Ravid Straussman; Joan Levy; Louise M Perkins; Jonathan J Keats; Steven E Schumacher; Mara Rosenberg; Gad Getz; Todd R Golub
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743
View more
  5 in total

1.  Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.

Authors:  Arghya Ray; Yan Song; Ting Du; Dharminder Chauhan; Kenneth C Anderson
Journal:  Oncogene       Date:  2020-02-05       Impact factor: 9.867

2.  B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Expert Opin Biol Ther       Date:  2019-07-11       Impact factor: 4.388

3.  The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.

Authors:  Shih-Feng Cho; Liang Lin; Lijie Xing; Yuyin Li; Kenneth Wen; Tengteng Yu; Phillip A Hsieh; Nikhil Munshi; Joachim Wahl; Katja Matthes; Matthias Friedrich; Tara Arvedson; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Blood Adv       Date:  2020-09-08

4.  Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma.

Authors:  Dharminder Chauhan; Kenneth C Anderson; Arghya Ray; Yan Song; Ting Du; Leutz Buon; Yu-Tzu Tai
Journal:  Blood Cancer J       Date:  2022-04-01       Impact factor: 11.037

5.  A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.

Authors:  Lijie Xing; Liang Lin; Tengteng Yu; Yuyin Li; Shih-Feng Cho; Jiye Liu; Kenneth Wen; Phillip A Hsieh; Krista Kinneer; Nikhil Munshi; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Leukemia       Date:  2020-02-14       Impact factor: 11.528
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.